About

Beverly Rogers, MD, is a Professor of Pediatric Pathology at the University of Arizona College of Medicine. She completed her MD at the University of Texas Medical Branch in Galveston in 1982 and subsequently completed her residency in Pathology at Arizona Health Sciences Center in Tucson from 1982 to 1984. She further specialized in Pediatric Pathology through a fellowship at Texas Children's Hospital, Baylor College of Medicine in Houston, Texas, in 1988. Dr. Rogers holds board certification from the American Board of Pathology with a subspecialty in Pediatric Pathology. Her professional experience includes practicing pathology at Arizona Health Sciences Center and Baylor College of Medicine, with a focus on pediatric pathology. She is actively involved in research, education, and clinical programs within the department, contributing her expertise to the field of pediatric pathology.

Research topics

• Medicine
• Pathology
• Biology
• Immunology
• Virology

Selected publications

• Multidisciplinary assessment of the Abbott BinaxNOW SARS-CoV-2 point-of-care antigen test in the context of emerging viral variants and self-administration

  Scientific Reports · 2021 · 77 citations

  • Medicine
  • Internal medicine
  • Biology

  While there has been significant progress in the development of rapid COVID-19 diagnostics, as the pandemic unfolds, new challenges have emerged, including whether these technologies can reliably detect the more infectious variants of concern and be viably deployed in non-clinical settings as "self-tests". Multidisciplinary evaluation of the Abbott BinaxNOW COVID-19 Ag Card (BinaxNOW, a widely used rapid antigen test, included limit of detection, variant detection, test performance across different age-groups, and usability with self/caregiver-administration. While BinaxNOW detected the highly infectious variants, B.1.1.7 (Alpha) first identified in the UK, B.1.351 (Beta) first identified in South Africa, P.1 (Gamma) first identified in Brazil, B.1.617.2 (Delta) first identified in India and B.1.2, a non-VOC, test sensitivity decreased with decreasing viral loads. Moreover, BinaxNOW sensitivity trended lower when devices were performed by patients/caregivers themselves compared to trained clinical staff, despite universally high usability assessments following self/caregiver-administration among different age groups. Overall, these data indicate that while BinaxNOW accurately detects the new viral variants, as rapid COVID-19 tests enter the home, their already lower sensitivities compared to RT-PCR may decrease even more due to user error.

  PublisherOA PDFDOI

Frequent coauthors

• James P. Sung

  Providence College

  18 shared

• Halit Pınar

  University of Vermont

  18 shared

• Nancy L. Thompson

  12 shared

• Charles F. Timmons

  Southwestern Medical Center

  10 shared

• Kazuo Yashima

  Tottori University

  9 shared

• Zora R. Rogers

  Center for Cancer and Blood Disorders

  7 shared

• Michael B. Sporn

  6 shared

• Kathleen C. Flanders

  6 shared

Similar researchers at University of Arizona

• Jean-Luc Brédash-175
• Jeremy Garciah-129
• Noam Chomskyh-123
• Katia Cunhah-115
• Lisa M Rimszah-99